Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-12-23
1998-12-01
Owens, Amelia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549282, A61K 3135
Patent
active
058439900
ABSTRACT:
The invention relates to pyran-chromenone compounds, their synthesis and anti-HIV activity. Methods of synthesis are disclosed; the compounds have activity against reverse transcriptase. Biological compositions containing the compounds and method of treating patients are also disclosed.
REFERENCES:
Galinis, D. L., et al., Structure-Activity Modifications of the HIV-1 Inhibitors(+)-Calanolide A and (-)-Calanolide B.sup.1, J. Med. Chem. 1996, 39, 4507-4510. of Labelled Compound and Radiopharmaceuticals vol. XXXVIII, No. 12, 1996, 1077-1081.
Zembower, D. E., et al., Structural Analogues of the Calanolide Anti-HIV Agents. Modification of the trans-10, 11-Dimethyldihydropyran-12-olRing (Ring C).sup.1, J. Med. Chem. 1997, 40, 1005-1017.
Taylor, P. B., et al., Kinetic and Mutational Analysis of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibition by Inophyllums, a Novel Class of Non-nucleoside Inhibitors, The Journal of Biological Chemistry, 1994, 269, 6325-6331.
Stout, G. H., et al., The Structure of Costatolide, J. Org. Chem., 1964, 29, 3604-3609.
Kashman, Y., et al., J. Med. Chem., 1992, 35, 2735-2743.
Chenera, B., et al., J. Org. Chem., 1993, 58, 5605-5606.
Fuller, R. W., et al., Bioorg. Med. Chem. Lett., 1994, 4, 1961-1964.
Newman, R. A., et al., J. Chromatogr. B., 1994, 658, 129-133.
Kawazu, K., et al., Bull Chem. Res., Kyoto Univ, 1972, 50, 160-167; Chem. Abstr. 78:13744.
Patil, A.D., et al., J. Med. Chem., 193, 36, 4130-4138.
Polonsky, J., Bull. Soc. Chim. Fr., 1956, 914-922.
Polonsky, J., et al., Bull. Soc. Chim. Fr., 1958, 929-944.
Rao, A. V. R., et al., Tetrahedron Lett., 1994, 35, 6347-6350.
Deshpande, P. P., et al., A Single Approach to the Synthesis of the Chiral Substituted Chroman Ring of Calophyllum Coumarins, synth:w95:w61, 1995.
Deshpande, P. P., et al., Synthesis of Optically Active Calonolides A and B, J. Org. Chem., 1995, 60, 2964-2965.
Baker, D. C., et al., Synthesis of Enantiomerically Pure Drugs From Sugars, Abstract No. 75, Presented at 29th ACS Middle Atlantic Regional Meeting, May 24-26, 1995.
Spence, Rebecca A., et al., Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors, Science, 1995, 267, 988-993.
Enger, C., PhD., et al., Survival From Early, Intermediate, and Late Stages of HIV Infection,Abstract, JAMA, 1996, 275, 1329-1334.
Kawazu, K., et al., The Piscicidal Constituents of Calophyllum Inophyllum Linn., Tetrahedron Letters, 1968, 19, 2383-2385.
Rehder, K. S., et al., Total Synthesis of (+)-Calanolide A, Synthetic Communications, 1996, 26(21), 4005-4021.
Ishikawa, T., et al., Cesium Fluoride-Induced Intramolecular Michael Addition: Highly Diastereoselective Ring Construction of a trans-2,3-Dimethylchroman-4-one,J. Org. Chem.,1996, 61, 6484-6485.
Khilevich, A., et al., Synthesis of (+)-Calonide, A, An Anti-HIV Agent, Via Enzyme-Catalyzed Resolution Of The Aldol Products, Tetrahedron: Asymmetry, 1996, 7(11), 3315-3326.
McKee, Tawnya C., et al., New Pyranocoumarins Isolated from Calopyllum lanigerum and Calophyllum teysmannii, J. Nat. Prod., 1996, 59, 754-758.
Khilevich, A., et al., A Versatile Approach For Synthesis Of 2,3-Dimethyl Chroman-4-Ones, Intermediate For Calanolide Anti-HIV Agents, Via Aldol/Mitsunobu Reactions, Synthetic Communications, 1996, 26(20), 3757-3771.
Currens, M. J., et al., Abstract, Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by Calanolide A, Journal of Pharmacology and Experimental Therapeutics, 1996, 279, 652-661.
Currens, M. J., et al., Abstract, Antiviral activity and mechanism of action of Calanolide A against the human immunodeficiency virus type-1, Journal of Pharmacology and Experimental Therapeutics, 1996, 279, 645-651.
Hammer, S. M., et al., A Controlled Trial of Two Nucleoside Analogues Plus Indivavir In Persons With Human Immunodeficiency Virus Infection and CD4 Cell Counts Of 200 Per Cubic Millimeter Or Less, Abstract, The New England Journal of Medicine, 1997, 337, 725-733.
Gulick, R. M., et al., Treatment With Indinavir, Zidovudine, And Lamivudine In Adults With Human Immunodeficiency Virus Infection And Prior Antiretroviral Therapy, Abstract, The New England Journal of Medicine, 1997, 337, 734-739.
Buckheit, R. W., et al., Abstract, A diarylsulphone non-nucleoside reverse transcriptase inhibitor with a unique sensitivity profile to drug-resistant virus isolates, Antiviral Chemistry & Chemotherapy, 1996, 7, 243-252.
Ohta, Y. and Shinkai, Ichiro, New Drugs--Reports of New Drugs Recently Approved by the FDA, Lamivudine, Bioorganic & Medicinal Chemistry, 1997, 5, 639-640.
Owens Amelia
The University of Tennessee Research Corporation
LandOfFree
Pyran-chromenone compounds, their synthesis and anti-HIV activit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyran-chromenone compounds, their synthesis and anti-HIV activit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyran-chromenone compounds, their synthesis and anti-HIV activit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2396078